Patents

US 12419937 B2: High concentration alpha-glucosidase compositions for the treatment of Pompe disease

Granted
2025-09-23
Filed
2022-03-21 application 17699910
Type
Utility · 18 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present application provides for compositions comprising high concentrations of acid α-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid α-glucosidase enzyme formulation.

Source: PVGPATDIS, file of 2026-04-10 (ipg250923.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Amicus Therapeutics, Inc. 158 patentsUS company or organizationPhiladelphia, PAAMICUS THERAPEUTICS, INC. Form D issuer EXACT high confidence: identical full name and state
AMICUS THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Kenneth ValenzanoEast Brunswick Township, NJ13PVGPATDIS, file of 2026-04-10
John CrowleyPrinceton, NJ6PVGPATDIS, file of 2026-04-10
Richie KhannaRaritan, NJ14PVGPATDIS, file of 2026-04-10
John FlanaganHickory Corner, NJ16PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K38/47PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P1/16PVGPATDIS, file of 2026-04-10
C12NMicroorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture mediaC12N9/2408PVGPATDIS, file of 2026-04-10
C12YEnzymesC12Y302/0102PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2026-04-27Release of security interest
Release of security interest
WILMINGTON TRUST, NATIONAL ASSOCIATION signed 2026-04-27AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA75494/30PASDL, file of 2026-08-13
2026-04-27Security interest Security interest
Security interest
BIOMARIN PHARMACEUTICAL INC. signed 2026-04-27
AMICUS THERAPEUTICS, INC. signed 2026-04-27
CITIBANK, N.A., AS COLLATERAL AGENT NEW YORK, NY75493/968PASDL, file of 2026-10-15
2023-10-06Security interest Security interest
Security interest
AMICUS THERAPEUTICS, INC. signed 2023-10-05WILMINGTON TRUST, NATIONAL ASSOCIATION MINNEAPOLIS, MN65177/196PASDL, file of 2026-10-15
2023-01-20Assignment
Assignment of assignor's interest
KHANNA, RICHIE signed 2014-09-09
VALENZANO, KENNETH signed 2014-09-09
FLANAGAN, JOHN signed 2014-09-14
CROWLEY, JOHN signed 2014-10-13
AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA62441/259ECORSEXC, file of 2026-09-25
2022-07-11Assignment
Assignment of assignor's interest
CORL, JONAS D. signed 2018-07-27
MITCHELL, THOMAS A signed 2018-07-27
INC., WAVEFRONT R NORTHAMPTON, PA60476/813ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.